Levi & Korsinsky Investigates Intellia Therapeutics, Inc. for Potential Securities Law Violations
New York, NY – February 4, 2025
Levi & Korsinsky, a leading securities law firm, notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. (NASDAQ: NTLA) for potential violations of federal securities laws. The investigation follows Intellia’s press release on January 9, 2025, where the company announced its strategic priorities and key anticipated 2025 milestones.
Background
Intellia Therapeutics is a leading genome editing company focused on developing proprietary CRISPR/Cas9 technology for therapeutic applications. The company’s press release highlighted its plans to advance its pipeline of gene-editing therapies, collaborations, and strategic partnerships. Intellia’s stock price increased by over 10% following the announcement.
Investigation Details
Levi & Korsinsky’s investigation focuses on whether Intellia Therapeutics and certain of its officers or directors made false and/or misleading statements and/or failed to disclose material information in connection with the company’s press release. Specifically, the investigation concerns whether the company’s statements regarding its pipeline, collaborations, and strategic partnerships were accurate and complete.
Impact on Individual Investors
If it is determined that Intellia Therapeutics and its officers or directors have engaged in securities fraud or other unlawful business practices, investors may be able to recover their losses through a securities class action lawsuit. Investors who purchased Intellia Therapeutics securities between the time of the false statements and the filing of a class action lawsuit may be eligible to participate in the case.
- If you purchased Intellia Therapeutics securities between January 9, 2025, and the filing of a class action lawsuit, you may be eligible to recover your losses.
- To learn more about the investigation and your rights, contact Levi & Korsinsky at (212) 363-7576 or submit the form on the firm’s website: [email protected].
Impact on the World
The investigation of Intellia Therapeutics could have significant implications for the broader biotech industry, as it highlights the importance of transparency and accuracy in communications regarding clinical trials, partnerships, and pipeline developments. The outcome of the investigation could also impact investor confidence in the biotech sector and potentially influence regulatory scrutiny of gene-editing technologies.
Conclusion
The investigation of Intellia Therapeutics by Levi & Korsinsky serves as a reminder for companies to ensure the accuracy and completeness of their public disclosures. Investors who have purchased Intellia Therapeutics securities between the time of the alleged false statements and the filing of a class action lawsuit may be eligible to recover their losses. For more information about the investigation and your potential eligibility, contact Levi & Korsinsky at (212) 363-7576 or submit the form on the firm’s website.
Stay informed about ongoing investigations and potential legal actions by following Levi & Korsinsky on Twitter: @LeviKorsinsky
